| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 04/10/2003 | CA2462112A1 Spiro-hydantoin compounds useful as anti-inflammatory agents |
| 04/10/2003 | CA2461877A1 Method of treatment using ligand-immunogen conjugates |
| 04/10/2003 | CA2461606A1 Nonhuman mammal model of autoimmune disease having ox40l gene transferred thereinto |
| 04/10/2003 | CA2461292A1 Apo-2 ligand variants and uses thereof |
| 04/10/2003 | CA2460916A1 Methods and compositions for modulating interleukin-21 receptor activity |
| 04/10/2003 | CA2459825A1 Compounds useful as reversible inhibitors of cysteine proteases |
| 04/10/2003 | CA2455389A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 04/10/2003 | CA2455225A1 Novel proteins and nucleic acids encoding same |
| 04/09/2003 | EP1300468A2 TRNA synthetase |
| 04/09/2003 | EP1300419A1 Antibody of human origin for inhibiting thrombocyte aggregation |
| 04/09/2003 | EP1300405A1 Amino alcohol derivatives |
| 04/09/2003 | EP1300401A1 Five-membered-ring compound |
| 04/09/2003 | EP1300138A2 Agents effective against hyperreactive and hypoactive deficient skin conditions as well as manifest dermatitis |
| 04/09/2003 | EP1299560A2 Identification and modulation of t helper-1 and t helper-2 cells |
| 04/09/2003 | EP1299546A2 Aminoacyl trna synthetases |
| 04/09/2003 | EP1299545A2 Drug metabolizing enzymes |
| 04/09/2003 | EP1299542A2 Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof |
| 04/09/2003 | EP1299538A2 Secreted proteins |
| 04/09/2003 | EP1299522A2 Alteration of cell membrane |
| 04/09/2003 | EP1299424A1 COLD WATER SOLUBLE $g(b)-GLUCAN PRODUCT AND PROCESS FOR PREPARING THE SAME |
| 04/09/2003 | EP1299421A2 Antibodies to human mcp-1 |
| 04/09/2003 | EP1299415A1 Chemokine receptor modulators, production and use |
| 04/09/2003 | EP1299412A2 Protein modification and maintenance molecules |
| 04/09/2003 | EP1299392A2 Glucocortiocoid-selective antiinflammatory agents |
| 04/09/2003 | EP1299385A2 Fused cyclic modulators of nuclear hormone receptor function |
| 04/09/2003 | EP1299378A1 Tetrahydropyridino or piperidino heterocyclic derivatives |
| 04/09/2003 | EP1299374A1 Novel non-psychotropic cannabinoids |
| 04/09/2003 | EP1299361A1 Pyrazole derivatives |
| 04/09/2003 | EP1299356A1 Novel compounds |
| 04/09/2003 | EP1299355A2 (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors |
| 04/09/2003 | EP1299351A1 Novel aryl, alkenyl, and alkynl 4-dedimethylaminotetracycline derivatives |
| 04/09/2003 | EP1299350A1 Substituted benzamides for immune enhancement and for the treatment of cancer, infection and manic-depressive illness |
| 04/09/2003 | EP1299128A2 Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination |
| 04/09/2003 | EP1299119A2 Immunosuppressive compositions comprising an immunophilin-binding compound and a ginkgolide compound |
| 04/09/2003 | EP1299118A2 Production and use of derivatized homoserine lactones |
| 04/09/2003 | EP1299117A2 Vaccine against helicobacter pylori |
| 04/09/2003 | EP1299115A2 Methods and compositions for developing spore display systems for medicinal and industrial applications |
| 04/09/2003 | EP1299113A2 Use of the heat shock protein gp96 |
| 04/09/2003 | EP1299032A1 DNA encoding human serine protease D-G |
| 04/09/2003 | EP1220844B1 Aryl sulfonamide-substituted benzimidazol derivatives thereof as tryptase inhibitors |
| 04/09/2003 | EP1094824A4 Prophylactic and therapeutic nutritional supplement for creation/maintenance of health-protective intestinal microflora and enhancement of the immune system |
| 04/09/2003 | EP1001766B1 Compounds for the treatment of ccr5-mediated diseases |
| 04/09/2003 | EP0963197A4 Guanylhydrazones useful for treating diseases associated with t cell activation |
| 04/09/2003 | EP0934280B1 Pde iv inhibiting 2-cyanoiminoimidazole derivatives |
| 04/09/2003 | EP0906303B1 Ring-fused dihydropyranes, process for the preparation and use thereof |
| 04/09/2003 | EP0804552B1 Redirection of cellular immunity by receptor chimeras |
| 04/09/2003 | EP0725824B1 Immunodominant human t-cell epitopes of hepatitis c virus |
| 04/09/2003 | EP0723455B1 Method of inhibiting phagocytosis |
| 04/09/2003 | EP0708768B1 Tri-substituted imidazoles having multiple therapeutic properties |
| 04/09/2003 | CN1409726A Type I cytokine receptor TCCR |
| 04/09/2003 | CN1409721A Treatment of viral infections using LEVOVIRIN |
| 04/09/2003 | CN1409720A Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| 04/09/2003 | CN1409715A Cyclopenteneone derivatives |
| 04/09/2003 | CN1409712A Pyrrolo [2,3-d] pyrimidine compounds |
| 04/09/2003 | CN1409639A TNF-alpha antagonist and LFA-1 antagonist for treating LFA-1 or TNF-alpha mediated disorder |
| 04/09/2003 | CN1409635A Treatment of systemic lupus erythematosus with dehydroepiandrosterone |
| 04/09/2003 | CN1408880A Detecting and trapping receptor 3 monoclonal antibody, hybrid tumor for producing said antibody and its use |
| 04/09/2003 | CN1408442A Adsorbent for whole blood perfusion adsorbing therapy |
| 04/09/2003 | CN1408429A Preparation of extramembranou section of therapeutic protein B lymphocyte stimulation factor |
| 04/09/2003 | CN1408387A Tea essence compound medicine and its preparing method |
| 04/09/2003 | CN1408367A Producing process for chick spleen transfer factor and its extracting method |
| 04/09/2003 | CN1105112C Benzothiophenecarboxamide derivatives and PGD2 antagonist comprising them |
| 04/09/2003 | CN1105100C Compound with anti-inflammatory and immunosuppressive activities |
| 04/09/2003 | CN1104909C Composition for prevention and treatment of HIV-1 infection comprising at least two different HIV-1 reverse transcriptase inhibitors |
| 04/09/2003 | CN1104900C Use of 8,9-dehydroestrone as anti-oxidant |
| 04/09/2003 | CN1104896C RAR-gamma antagonist ligand or RAR-alpha agonist ligand as apoptosis inhibitor |
| 04/08/2003 | WO2002034715A1 Benzamidine derivatives comprising a sulfate group serving as ltb4 antagonists |
| 04/08/2003 | US6545182 Methods and compositions for modulating alpha adrenergic receptor activity |
| 04/08/2003 | US6545137 Autoimmune diseases; antiinflammatory agents; viricides; antidiabetic agents; binding to low density lipoproteins |
| 04/08/2003 | US6545124 Antiproliferative agents |
| 04/08/2003 | US6545050 Aryl sulphonamide amino acid esters and analogues |
| 04/08/2003 | US6545049 E.g., (2E, 4E, 6E)-7-(3,5-diisopropyl-2-n-heptyloxyphenyl)-3-methylocta-2,4,6-trienoic acid, esters or amides thereof |
| 04/08/2003 | US6545041 Tumor necrosis factor alpha (TNF-α) inhibiting pharmaceuticals |
| 04/08/2003 | US6545038 Heterocyclic metalloprotease inhibitors |
| 04/08/2003 | US6545030 1-heterocycle substituted diarylamines |
| 04/08/2003 | US6545023 For treating rheumatoid arthritis; for examle, 1-(4-(4-fluorophenyl)piperidin-1-yl),3-(2-methoxy-4 -chlorobenzylaminocarbonyl),3-isopropyl-cyclopentane |
| 04/08/2003 | US6545013 2,7-naphthyridine derivatives |
| 04/08/2003 | US6545005 Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| 04/08/2003 | US6545004 Treating cellular proliferative diseases and disorders associated with KSP kinesin activity. |
| 04/08/2003 | US6545003 Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 04/08/2003 | US6544995 Use of cysteine derivatives for preparing a medicine for treating pathologies resulting from the formation of heterotrimeric G protein |
| 04/08/2003 | US6544977 Crystalline forms of 1s-[1-alpha(2s*,3r*), 9alpha]6, 10-dioxo-n-(2-ethoxy-5-oxo-tetrahydro-3-furanyl)-9[[(1-isoquinolyl)carbonyl]amino]octahydro-6h-pyridazino [1,2-a] [1,2] diazepin-1-carboxamide |
| 04/08/2003 | US6544951 Antiinflammatory agents; autoimmune diseases, nervous system degradation |
| 04/08/2003 | US6544547 Nutritional composition containing methionine |
| 04/08/2003 | US6544541 Devices and compounds for treating arterial restenosis |
| 04/08/2003 | US6544530 Stable oil-in-glycerin emulsion |
| 04/08/2003 | US6544523 Mutant forms of Fas ligand and uses thereof |
| 04/08/2003 | US6544518 Vaccines |
| 04/08/2003 | US6544514 Compositions comprising, as the main ingredient, allogenic activated-C4+ cells and method for producing and using the same |
| 04/08/2003 | US6544510 Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications |
| 04/08/2003 | US6544509 Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications |
| 04/08/2003 | US6544508 Escherichia coli strain BU-230-98 ATCC Deposit No. 20226 (DSM 12799) |
| 04/08/2003 | CA2065849C Vitamin d analogues |
| 04/08/2003 | CA2053216C Saturated hydroxyalkylquinoline acids as leukotriene antagonists |
| 04/08/2003 | CA2050300C Tnf-inhibiting proteins and the preparation thereof |
| 04/07/2003 | WO2002032866A1 (4-acylaminopiperidin-1-yl) acetamides as neurokinin antagonists |
| 04/04/2003 | CA2406610A1 Embryonic stem cells and neural progenitor cells derived therefrom |
| 04/03/2003 | WO2003027282A1 Adamts-15, -16, -17, -18 and -19 |
| 04/03/2003 | WO2003027263A2 Proteins associated with cell growth, differentiation, and death |
| 04/03/2003 | WO2003027232A2 Method for producing biologically active products |